Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 392

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Open access
Cooper, Matthew L, Choi, Jaebok, Staser, Karl, Ritchey, Julie K, Devenport, Jessica M, Eckardt, Kayla, Rettig, Michael P, Wang, Bing, Eissenberg, Linda G, Ghobadi, Armin, Gehrs, Leah N, Prior, Julie L, Achilefu, Samuel, Miller, Christopher A, Fronick, Catrina C, O’Neal, Julie, Gao, Feng, Weinstock, David M, Gutierrez, Alejandro, Fulton, Robert S, DiPersio, John F·2018·Leukemia

Abstract

T cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T cells and malignant T cells has limited the development of CAR-T because of unintended CAR-T fratricide and an inability to harvest sufficient autologous T cells. Here, we describe a fratricide-resistant “off-the-shelf” CAR-T (or UCART7) that targets CD7+ T cell malignancies and, through CRISPR/Cas9 gene editing, lacks both CD7 and T cell receptor alpha chain (TRAC) expression. UCART7 demonstrates efficacy against human T cell acute lymphoblastic leukemia (T-ALL) cell lines and primary T-ALL in vitro and in vivo without the induction of xenogeneic GvHD. Fratricide-resistant, allo-tolerant “off-the-shelf” CAR-T represents a strategy for treatment of relapsed and refractory T-ALL and non-Hodgkin’s T cell lymphoma without a requirement for autologous T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0065-5

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 392

Metadata

Authors
Cooper, M. L., Choi, J., Staser, K., Ritchey, J. K., Devenport, J. M., Eckardt, K., Rettig, M. P., Wang, B., Eissenberg, L. G., Ghobadi, A., Gehrs, L. N., Prior, J. L., Achilefu, S., Miller, C. A., Fronick, C. C., O’Neal, J., Gao, F., Weinstock, D. M., Gutierrez, A., Fulton, R. S., & DiPersio, J. F.
Venue
Leukemia
Published
2018-02-20
Volume
32
Issue
9
Pages
1970-1983
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2791923357
Cited by
392
References
34
FWCI
13.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. https://app.cochat.ai/papers/10.1038/s41375-018-0065-5
The paper
Cooper, M. L., Choi, J., Staser, K., Ritchey, J. K., Devenport, J. M., Eckardt, K., Rettig, M. P., Wang, B., Eissenberg, L. G., Ghobadi, A., Gehrs, L. N., Prior, J. L., Achilefu, S., Miller, C. A., Fronick, C. C., O’Neal, J., Gao, F., Weinstock, D. M., Gutierrez, A., . . . DiPersio, J. F. (2018). An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. https://doi.org/10.1038/s41375-018-0065-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.